Table of Contents
Will large pharma's AI adoption and deployment to drug development redefine biotech's role and business model? Has Europe missed the opportunity arising from U.S. market uncertainty?
And how can companies prepare for therapeutic commercialization under ever-shifting governments?
Treehill Partners is an international strategic and financial advisory firm focused exclusively on healthcare.
At JPM 2026, Treehill ran a series of closed-door roundtables exploring the most pertinent topics in biotech and pharma.
Onyx sat down with co-founder Max Baumann to find out more.
I hope you enjoy watching!
Yours sincerely,
Dr. Adil Ali
Comments